Drug Trial Radar · NCT07175441
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Apr 10, 2026
Primary completion
Apr 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Riboscience, LLC.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
Conditions
- Advanced Unresectable Hepatocellular Carcinoma
Interventions
RBS2418Drug
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
STRIDE (durvalumab + tremelimumab)Drug
STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
START Dallas Fort Worth
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.